- Home
- MNMD vs SHBI Comparison
MNMD vs SHBI Comparison
Compare MNMD & SHBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- SHBI
- Stock Information
- Founded
- MNMD 2019
- SHBI 1876
- Country
- MNMD United States
- SHBI United States
- Employees
- MNMD N/A
- SHBI N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- SHBI Major Banks
- Sector
- MNMD Health Care
- SHBI Finance
- Exchange
- MNMD Nasdaq
- SHBI Nasdaq
- Market Cap
- MNMD 509.2M
- SHBI 532.0M
- IPO Year
- MNMD N/A
- SHBI N/A
- Fundamental
- Price
- MNMD $9.22
- SHBI $16.95
- Analyst Decision
- MNMD Strong Buy
- SHBI Buy
- Analyst Count
- MNMD 7
- SHBI 1
- Target Price
- MNMD $24.71
- SHBI $20.00
- AVG Volume (30 Days)
- MNMD 1.2M
- SHBI 121.6K
- Earning Date
- MNMD 11-06-2025
- SHBI 10-23-2025
- Dividend Yield
- MNMD N/A
- SHBI 2.83%
- EPS Growth
- MNMD N/A
- SHBI 169.45
- EPS
- MNMD N/A
- SHBI 1.61
- Revenue
- MNMD N/A
- SHBI $208,209,000.00
- Revenue This Year
- MNMD N/A
- SHBI N/A
- Revenue Next Year
- MNMD N/A
- SHBI $16.05
- P/E Ratio
- MNMD N/A
- SHBI $10.52
- Revenue Growth
- MNMD N/A
- SHBI 24.24
- 52 Week Low
- MNMD $4.70
- SHBI $11.47
- 52 Week High
- MNMD $11.02
- SHBI $17.61
- Technical
- Relative Strength Index (RSI)
- MNMD 47.40
- SHBI 59.10
- Support Level
- MNMD $8.70
- SHBI $16.80
- Resistance Level
- MNMD $9.30
- SHBI $17.29
- Average True Range (ATR)
- MNMD 0.58
- SHBI 0.32
- MACD
- MNMD -0.13
- SHBI 0.07
- Stochastic Oscillator
- MNMD 22.41
- SHBI 70.22
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About SHBI Shore Bancshares Inc
Shore Bancshares Inc is a financial holding company. It offers personalized banking, insurance, and investment services to families and businesses in the Mid-Atlantic region. It operates in one business segment- banking. The company's primary source of revenue is derived from interest earned on commercial, residential mortgage and other loans, and fees charged in connection with lending and other banking services located in Maryland, Delaware and Virginia.